This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (83)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Patient-Physician Relationship/ Care  • Treatment Adherence  • Cardiovascular System  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Adherence  • Alert me on articles by topic  Social Bookmarking   What's this?

Jeppe N. Rasmussen, MD; Alice Chong, BSc; David A. Alter, MD, PhD, FRCPC

JAMA. 2007;297:177-186.

Context  The extent to which drug adherence may affect survival remains unclear, in part because mortality differences may be attributable to "healthy adherer" behavioral attributes more so than to pharmacological benefits.

Objective  To explore the relationship between drug adherence and mortality in survivors of acute myocardial infarction (AMI).

Design, Setting, and Participants  Population-based, observational, longitudinal study of 31 455 elderly AMI survivors between 1999 and 2003 in Ontario. All patients filled a prescription for statins, -blockers, or calcium channel blockers, with the latter drug considered a control given the absence of clinical trial–proven survival benefits.

Main Outcome Measures  Patient adherence was subdivided a priori into 3 categories—high (proportion of days covered, 80%), intermediate (proportion of days covered, 40%-79%), and low (proportion of days covered, <40%)—and compared with long-term mortality (median of 2.4 years of follow-up) using multivariable survival models (and propensity analyses) adjusted for sociodemographic factors, illness severity, comorbidities, and concomitant use of evidence-based therapies.

Results  Among statin users, compared with their high-adherence counterparts, the risk of mortality was greatest for low adherers (deaths in 261/1071 (24%) vs 2310/14 345 (16%); adjusted hazard ratio, 1.25; 95% confidence interval, 1.09-1.42; P = .001) and was intermediary for intermediate adherers (deaths in 472/2407 (20%); adjusted hazard ratio, 1.12; 95% confidence interval, 1.01-1.25; P = .03). A similar but less pronounced dose-response–type adherence-mortality association was observed for -blockers. Mortality was not associated with adherence to calcium channel blockers. Moreover, sensitivity analyses demonstrated no relationships between drug adherence and cancer-related admissions, outcomes for which biological plausibility do not exist.

Conclusion  The long-term survival advantages associated with improved drug adherence after AMI appear to be class-specific, suggesting that adherence outcome benefits are mediated by drug effects and do not merely reflect an epiphenomenon of "healthy adherer" behavioral attributes.

Author Affiliations: Institute of Clinical Evaluative Sciences (Drs Rasmussen and Alter and Ms Chong), Clinical Epidemiology Unit, Sunnybrook Health Sciences Centre (Dr Alter), Division of Cardiology and the Li Ka Shing Knowledge Institute of St Michael's Hospital (Dr Alter), and Departments of Medicine and Health Policy, Management, and Evaluation, University of Toronto (Dr Alter), Toronto, Ontario; and National Institute of Public Health, Copenhagen, Denmark (Dr Rasmussen).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

{beta}-Blocker Compliance, Mortality, and Reinfarction: Validation of Clinical Trial Association Using Insurer Claims Data
Kleiner et al.
American Journal of Medical Quality 2009;24:512-519.
ABSTRACT  

Adherence to Antihypertensive Medications and Cardiovascular Morbidity Among Newly Diagnosed Hypertensive Patients
Mazzaglia et al.
Circulation 2009;120:1598-1605.
ABSTRACT | FULL TEXT  

ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease.
American College of Cardiology Foundation et al.
J Am Coll Cardiol 2009;54:1336-1363.
FULL TEXT  

ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease: A Report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): Developed in Collaboration With the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association
WRITING COMMITTEE MEMBERS et al.
Circulation 2009;120:e100-e126.
FULL TEXT  

We need minimally disruptive medicine
May et al.
BMJ 2009;339:b2803-b2803.
FULL TEXT  

Medication Adherence: Its Importance in Cardiovascular Outcomes
Ho et al.
Circulation 2009;119:3028-3035.
ABSTRACT | FULL TEXT  

Medication Adherence in Healthy Elders: Small Cognitive Changes Make a Big Difference
Hayes et al.
J Aging Health 2009;21:567-580.
ABSTRACT  

Management of Hyperlipidemia in Older Adults
Alexander et al.
J CARDIOVASC PHARMACOL THER 2009;14:49-58.
ABSTRACT  

Copayment Levels and Medication Adherence: Less Is More
Choudhry
Circulation 2009;119:365-367.
FULL TEXT  

Depression and heart disease: What do we know, and where are we headed?
POZUELO et al.
Cleveland Clinic Journal of Medicine 2009;76:59-70.
ABSTRACT | FULL TEXT  

Nonadherence to antiepileptic drugs and increased mortality: Findings from the RANSOM Study
Faught et al.
Neurology 2008;71:1572-1578.
ABSTRACT | FULL TEXT  

Improving Medication Adherence in Chronic Cardiovascular Disease
Albert
Crit Care Nurse 2008;28:54-64.
FULL TEXT  

Discontinuation of statin therapy following an acute myocardial infarction: a population-based study
Daskalopoulou et al.
Eur Heart J 2008;29:2083-2091.
ABSTRACT | FULL TEXT  

Associations of Kidney Function with Cardiovascular Medication Use after Myocardial Infarction
Winkelmayer et al.
CJASN 2008;3:1415-1422.
ABSTRACT | FULL TEXT  

Outcomes Research: Generating Evidence for Best Practice and Policies
Krumholz
Circulation 2008;118:309-318.
FULL TEXT  

Lipid Levels in the Post-Acute Coronary Syndrome Setting: Destabilizing Another Myth?
Miller
J Am Coll Cardiol 2008;51:1446-1447.
FULL TEXT  

Improving the Quality of Measurement and Evaluation in Quality Improvement Efforts
Pronovost et al.
American Journal of Medical Quality 2008;23:143-146.
 

The year in atherothrombosis.
Sanz et al.
J Am Coll Cardiol 2008;51:944-955.
FULL TEXT  

Factors Related to Adherence to Statin Therapy
McGinnis et al.
The Annals of Pharmacotherapy 2007;41:1805-1811.
ABSTRACT | FULL TEXT  

The Year in Non ST-Segment Elevation Acute Coronary Syndrome
Giugliano and Braunwald
J Am Coll Cardiol 2007;50:1386-1395.
FULL TEXT  

Self-reported Medication Adherence and Cardiovascular Events in Patients With Stable Coronary Heart Disease: The Heart and Soul Study
Gehi et al.
Arch Intern Med 2007;167:1798-1803.
ABSTRACT | FULL TEXT  

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
Anderson et al.
J Am Coll Cardiol 2007;50:e1-e157.
FULL TEXT  

Persistent Use of Evidence-Based Pharmacotherapy in Heart Failure Is Associated With Improved Outcomes
Gislason et al.
Circulation 2007;116:737-744.
ABSTRACT | FULL TEXT  

Mortality and Adherence to Pharmacotherapy After Acute Myocardial Infarction
Parakh et al.
JAMA 2007;297:1877-1877.
FULL TEXT  

Mortality and Adherence to Pharmacotherapy After Acute Myocardial Infarction
Kinjo et al.
JAMA 2007;297:1877-1878.
FULL TEXT  

Performance Measures and Outcomes for Patients Hospitalized With Heart Failure
Shishehbor and Litaker
JAMA 2007;297:1547-1547.
FULL TEXT  

Adherence to drug treatments prolongs survival after heart attack
BMJ 2007;334:118-118.
FULL TEXT